Back to Authors

Chen, John J

0000-0003-3644-7528

Mayo Clinic

Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN.

Citations 143

Outcomes of Maintenance Immunotherapy in a Cohort of Patients With Susac Syndrome

Neurology Clinical Practice | October 2, 2025 | Volume: 15 | Issue: 6 | Pages: No page available

10.1212/cpj.0000000000200544 | PMID 41070138

Amaurosis Fugax Dolorosa

Neurology Neuroimmunology & Neuroinflammation | September 22, 2025 | Volume: 12 | Issue: 6 | Pages: No page available

10.1212/nxi.0000000000200471 | PMID 40982779

Outcomes After Acute Plasma Exchange for Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

Neurology | August 29, 2025 | Volume: 105 | Issue: 6 | Pages: No page available

10.1212/wnl.0000000000213903 | PMID 40882166

Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease Optic Neuritis With Venous Stasis Retinopathy

Neurology | August 25, 2025 | Volume: 105 | Issue: 6 | Pages: No page available

10.1212/wnl.0000000000214038 | PMID 40854174

3D Deep Learning Analysis of OCT to Classify Optic Atrophy

JAMA Ophthalmology | August 21, 2025 | Volume: 143 | Issue: 10 | Pages: 811

10.1001/jamaophthalmol.2025.2829 | PMID 40839376

Application of the ADEM definition to cerebral attacks of MOG antibody-associated disease

Multiple Sclerosis Journal | August 19, 2025 | Volume: 31 | Issue: 14 | Pages: 1629-1640

10.1177/13524585251359450 | PMID 40827744

Background: Acute disseminated encephalomyelitis (ADEM) is a demyelinating syndrome observed in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) but there are limited data on application of this definition to its cerebral attacks or in adults with this disease. Methods: We analyzed patients from the Mayo Clinic MOGAD cohort ( n = 263) with cerebral attacks. We assessed whether children (<18 years-old) and adults (⩾18 years-old) fulfilled the 2013 ADEM definition. Results: We identified 89 patients (children, 34; adults, 55) and 55/89 (62%) were of female sex. Acute magnetic resonance imaging (MRI) abnormalities included: poorly demarcated T2 lesions (white matter, 85 (96%); deep gray matter, 41 (46%); T1-hypointense lesions (42 (47%)). Forty-two patients did not fulfill the ADEM definition due to: monofocal syndrome, 9; or no encephalopathy, 33. The remaining 47 patients (53%: children, 27/34 (79%); adults, 20/55 (36%)) fulfilled the ADEM definition, and 14 had preceding attacks, and 34 had subsequent attacks relative to ADEM episode. The features in children and adults with ADEM were broadly comparable. Conclusion: Applying the ADEM definition to MOGAD cerebral attacks highlighted that an update of the 2013 ADEM definition would be beneficial and could explicitly state its application to both adults and children and allow it to be applied to attacks at any time during the disease course.
Unveiling Misdiagnosis: Rethinking Seronegative NMOSD

Multiple Sclerosis Journal | August 16, 2025 | Volume: 31 | Issue: 11 | Pages: 1381-1384

10.1177/13524585251360648 | PMID 40817768

Seronegative neuromyelitis optica spectrum disorder (NMOSD) is a diagnostic challenge. This study aimed to characterize misapplication of the 2015 international criteria for seronegative NMOSD. We reviewed 35 consecutive seronegative NMOSD referrals to a tertiary center. Two (6%) met formal criteria, and 2 (6%) were clinically suspected of NMOSD without fulfilling radiologic supportive criteria. Alternative diagnoses were common including multiple sclerosis (37%), optic neuritis (14%), functional neurologic disorder (11%), and other (38%). Immunosuppression with rituximab was used in 3 of 4 patients with functional neurologic disorder. Misapplication of the 2015 criteria is common, and alternative explanations in seronegative NMOSD patients should be strongly considered.
MRI characteristics during attack and remission distinguish patients with MOG antibody-associated disease from multiple sclerosis

Journal of Neurology, Neurosurgery & Psychiatry | July 20, 2025 | Volume: No volume available | Issue: No issue available | Pages: jnnp-2025-336684

10.1136/jnnp-2025-336684 | PMID 40685157

Background Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and multiple sclerosis (MS) have both overlapping and distinct MRI lesion features, which vary with imaging timing. This study identified distinguishing MRI characteristics using paired MRIs at clinical attack and remission. Methods We retrospectively identified Mayo Clinic patients with MOGAD and MS that: (1) fulfilled respective diagnostic criteria; (2) had paired attack (≤30 days) and remission MRI scans (≥12 months) without interval attacks. MRIs were compared between groups for key features. Results We included 43 patients with MOGAD (median age 31 years (range, 3–67); 63% female) and 49 patients with MS (median age 39 years (range, 17–65); 65% female). Resolution of at least one T2-lesion differentiated MOGAD from MS (sensitivity, (95% CI 77% to 100%), specificity, (95% CI 86% to 99%); Youden’s index (YI)=0.90). Resolution of at least two T2-lesions indicated MOGAD (sensitivity 62% (95% CI 41% to 79%); specificity, 100% (95% CI 94% to 100%); YI=0.62). MOGAD patients were more likely to have normal MRI scans at follow-up compared with MS (brain 14/44 (32%) vs 0/60 (0%), p<0.001; spine 21/27 (78%) vs 7/36 (19%), p<0.001). In addition, the presence of T1-hypointense, ovoid periventricular T2, and enhancing lesions were more common in MS versus MOGAD at attack and remission and in the spine, longitudinally extensive T2 lesions were more common in MOGAD attacks (8/27 (30%)). Conclusion Paired MRI at attack and remission revealed distinctive characteristics of MOGAD and MS, with greater diagnostic value at remission driven by the discriminating power of T2-lesion resolution. In MOGAD patients with initial parenchymal involvement, a 1-year follow-up MRI may aid diagnosis and serve as a new baseline.
Association of Semaglutide and NAION Reviewed—Reply

JAMA Ophthalmology | June 26, 2025 | Volume: 143 | Issue: 8 | Pages: 717

10.1001/jamaophthalmol.2025.1826 | PMID 40569577

Meningitis as an Attack Phenotype of Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

JAMA Neurology | June 16, 2025 | Volume: 82 | Issue: 8 | Pages: 871

10.1001/jamaneurol.2025.1774 | PMID 40522676

This international multicenter study seeks to determine the frequency and characteristics of meningitis in myelin oligodendrocyte glycoprotein antibody (MOGAD)–associated disease and highlight its pathology.